Q-omics provides the consensus-scored ZNF785 profile across patient tissues and cancer cell-line models. ZNF785 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF785 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZNF785 RNA expression shows 21,169 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where ZNF785 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF785 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF785 survival associations across molecular data types. ZNF785 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF785 RNA expression–survival associations across cancer types. High ZNF785 expression shows unfavorable associations in LIHC and COAD, but favorable associations in HNSC, THYM, BLCA and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF785 RNA expression.
This table summarizes ZNF785 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF785. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF785 shows higher tumor expression in KIRC, LIHC, STAD, HNSC, COAD and KIRP. The KIRC box plot shows higher ZNF785 RNA expression in tumor versus normal tissue (log2 FC = +0.684, t-test p < 0.001).
This table shows molecular features associated with ZNF785 in patient tissues and cancer cell lines. In patient samples, ZNF785 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF785 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
